Clinical trials: Cyclophosphamide
- Condition Cyclophosphamide
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
- Trial name
- THRIVE (NCT03699475)
- Testing
- rivogenlecleucel, rimiducid, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Progressive Solid Malignancies, Refractory Solid Malignancies
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study.
- Conditions
- Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
- Trial name
- NCT02224599
- Testing
- TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Kiromic BioPharma Inc.
Metabolic Disorders
A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
The purpose of this study is to describe the safety profile of ProHema-CB as part of a single cord blood unit transplant after a myeloablative conditioning regimen in pediatric patients with inherited metabolic disorders.
- Trial name
- PROVIDE (NCT02354443)
- Testing
- ProHema-CB Transplant
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fate Therapeutics
Vasculitis
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
- Trial name
- NCT06321601
- Testing
- Avacopan
- Where
- 34 sites in United States, Belgium and 8 more
- Volunteers
- 19 people
- Sponsor
- Amgen
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Ovarian Neoplasms
Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
Primary objective: To assess response rate. To record the clinical improvement in relation to stage and histopathological grading. Secondary objective: To determine progression free survival. To find out overall survival.
- Trial name
- OCSTUD (NCT00452985)
- Testing
- Docetaxel, Carboplatin
- Where
- Bangladesh
- Volunteers
- 30 people
- Sponsor
- Sanofi
Breast Cancer, Metastases
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to…
- Trial name
- NCT00099281
- Testing
- YMB 1002
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- YM BioSciences
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Relapsed Leukemia
- Trial name
- NCT00315705
- Testing
- clofarabine, Etoposide, Cyclophosphamide
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- Genzyme, a Sanofi Company
ANCA-Associated Vasculitis
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with…
- Trial name
- ADVOCATE (NCT02994927)
- Testing
- Avacopan, Prednisone, Cyclophosphamide
- Where
- 198 sites in United States, Australia and 18 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Lymphoblastic Leukemia, Acute, Childhood
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
This is an open-label study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine to assess this 5-drug treatment's safety and tolerability in pediatric patients with first relapse Acute Lymphoblastic…
- Trial name
- NCT00991133
- Testing
- Clofarabine incorporated into a 5-drug regimen
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Genzyme, a Sanofi Company
AL Amyloidosis
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04304144
- Testing
- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Ewing Sarcoma, Myxoid Liposarcoma
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination…
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT03600649
- Testing
- Seclidemstat, Cyclophosphamide, Topotecan
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Salarius Pharmaceuticals, LLC